Twist Bioscience Co. (NASDAQ:TWST – Get Free Report) COO Patrick John Finn sold 6,865 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total value of $296,636.65. Following the sale, the chief operating officer now directly owns 161,744 shares in the company, valued at approximately $6,988,958.24. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Patrick John Finn also recently made the following trade(s):
- On Monday, August 5th, Patrick John Finn sold 2,885 shares of Twist Bioscience stock. The shares were sold at an average price of $39.93, for a total value of $115,198.05.
- On Tuesday, July 23rd, Patrick John Finn sold 2,207 shares of Twist Bioscience stock. The stock was sold at an average price of $56.62, for a total value of $124,960.34.
Twist Bioscience Stock Performance
Twist Bioscience stock opened at $43.34 on Monday. Twist Bioscience Co. has a 1 year low of $14.42 and a 1 year high of $60.90. The firm’s 50 day moving average price is $44.94 and its two-hundred day moving average price is $43.75. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of -12.90 and a beta of 1.77.
Wall Street Analyst Weigh In
Several research firms recently weighed in on TWST. JPMorgan Chase & Co. upped their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Evercore ISI upped their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Robert W. Baird raised their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. The Goldman Sachs Group boosted their target price on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. Finally, Barclays decreased their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $51.63.
Get Our Latest Stock Analysis on Twist Bioscience
Institutional Trading of Twist Bioscience
Hedge funds have recently bought and sold shares of the company. EdgeRock Capital LLC purchased a new stake in shares of Twist Bioscience in the 2nd quarter valued at approximately $43,000. Blue Trust Inc. raised its stake in Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after purchasing an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in shares of Twist Bioscience in the second quarter valued at $61,000. Nisa Investment Advisors LLC boosted its position in shares of Twist Bioscience by 31.3% in the second quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock worth $113,000 after buying an additional 546 shares during the period. Finally, CWM LLC grew its holdings in shares of Twist Bioscience by 27.4% during the second quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after buying an additional 524 shares in the last quarter.
About Twist Bioscience
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
See Also
- Five stocks we like better than Twist Bioscience
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Key Stocks to Ride China’s Stimulus-Driven Growth
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- Market Cap Calculator: How to Calculate Market Cap
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.